PanACEA team together with collaborators at Uppsala University recently published a model-based study further elucidating how to optimally dose rifampicin. The work suggest that a staggered approach, starting a bit lower and then increasing doses, may improve the tolerability for patients and thereby enable the higher doses which we demonstrated earlier is beneficial in terms of efficacy. This innovative apprach is simple to implement, and should eb further investigated in clinical trials.
https://pubmed.ncbi.nlm.nih.gov/37037318/